ENLIVEN THERAPEUTICS, INC. Fair Value, Assets, Level 1 to Level 2 Transfers, Amount
ENLIVEN THERAPEUTICS, INC. (ELVN) had Fair Value, Assets, Level 1 to Level 2 Transfers, Amount of $0 as of 2022-03-31, per its 10-Q filed 2022-05-06.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount · last filed 2022-05-06
- 2022-03-31: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
- 2021-12-31: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
- 2021-09-30: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
- 2021-06-30: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
| Period end | Fair Value, Assets, Level 1 to Level 2 Transfers, Amount |
|---|---|
| 2022-03-31 | $0.00 10-Q · filed 2022-05-06 |
| 2021-12-31 | $0.00 10-Q · filed 2022-05-06 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-09 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-06 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-11 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-15 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-14 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |